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Background: Pulmonary fibrosis is a manifestation of microscopic polyangitis (MPA), and often
precedes the detection of MPA. The prevalence and sequence of myeloperoxidase anti-
neutrophil cytoplasmic antibody (MPO-ANCA) and MPA in patients initially diagnosed with idio-
pathic pulmonary fibrosis (IPF) have not been precisely elucidated.
Methods: We enrolled 61 consecutive patients with IPF and measured the MPO-ANCA titers at
initial presentation and during the follow-up period. Clinical, radiologic and histologic features
of MPO-ANCA-positive cases were examined.
Results: Of 61 patients, 3 (4.9%) had positive MPO-ANCA titers at the initial presentation of IPF.
During the disease course, MPO-ANCA-positive conversion occurred in 6 patients and the prev-
alence of ANCA increased to 14.8%. Among the nine patients positive for MPO-ANCA, two pa-
tients developed MPA during follow-up. Histologic features of MPO-ANCA-positive pulmonary
fibrosis were compatible with the usual interstitial pneumonia pattern in which alveolar hem-
orrhage and capillaritis were not observed. The patients with MPO-ANCA-positive conversion
showed increased percentages of bronchoalveolar lavage eosinophils and more frequentcytoplasmic antibodies; BAL, bronchoalveolar lavage; CVD-IP, collagen vascular disease-associated
solution computed tomography; IPF, idiopathic pulmonary fibrosis; MPA, microscopic polyangitis;
se; NSIP, nonspecific interstitial pneumonia.
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MPO-ANCA in the course of IPF 609complication of pulmonary emphysema compared to those with MPO-ANCA-negative IPF.
Conclusions: The findings of the present study demonstrated that patients with an initial diag-
nosis of IPF occasionally acquire MPO-ANCA, which develops to MPA during the disease course
of IPF. The presence of pulmonary eosinophilia and low attenuation areas on computed tomog-
raphy scans might be predictive of MPO-ANCA positive conversion.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Anti-neutrophil cytoplasmic antibodies (ANCA) are directed
against enzymes in the granules of polymorphonuclear
leukocytes and the major ANCA antigens are the myeloid
enzymes myeloperoxidase (MPO) and proteinase 3.1,2 ANCA
plays a role in both neutrophil activation and direct tissue
injury in vitro,3 suggesting that ANCA is involved in the
pathogenesis of systemic vascular disorders. Clinically,
ANCA is an important serum biomarker for diagnosing and
monitoring systemic vasculitis.4,5
Pulmonary lesions often accompany microscopic poly-
angitis (MPA) and manifest in patients with MPO-ANCA. Pul-
monary fibrosiswas present in 36%of patientswithMPAat the
time of diagnosis.6 A previous report demonstrated that
chronic interstitial lesions are common histologic features in
patients with MPO-ANCA based on the pathologic reviews.7,8
Thus, pulmonary fibrosis is now a recognized manifestation
of MPA. Nada et al. reported three patients initially diag-
nosed with idiopathic pulmonary fibrosis (IPF) that devel-
oped pulmonary-renal vasculitis.9 Since then, similar cases
have accumulated in small clinical series, suggesting that
patients with IPF can develop MPA. However, the association
and sequence of pulmonary fibrosis and MPO-ANCA positivity
and vasculitis has not been elucidated.
Here,we examined theMPO-ANCApositivity in consecutive
patientswith an initial diagnosis of IPFat hospital presentation
andduring the follow-upperiod, aswell as the incidenceof the
development to MPA. In addition, we examined clinical, radi-
ologic and histologic features of MPO-ANCA-positive patients.
Wealso aimedtocharacterize theclinical picturepredictiveof
MPO-ANCA-positive conversion in IPF.Methods
Patient selection
This study was approved by the Institutional Ethics Commit-
tee approval of Oita University (No.151). We reviewed 85
consecutivepatientswith IPFdiagnosedat theOitaUniversity
Hospital during the period between January 2000 and
December 2009. The diagnosis of IPFwasmade on the basis of
the criteria of the American Thoracic Society/European
Respiratory Society international multidisciplinary consensus
classification.10 Patients were considered to have undiffer-
entiated connective tissue disease (UCTD) if their medical
record identified signs/symptomsand laboratoryfindings that
met the criteria for UCTD as previously published.11
We analyzed the incidence of the development to MPA
during follow-up of the patients. MPAwas diagnosed based onthe Chapel Hill Consensus Conference nomenclature of sys-
temic vasculitis.12 To elucidate the incidence of MPO-ANCA
positivity and MPO-ANCA-positive conversion in patients
with IPF diagnosed at initial presentation, we excluded the
patients with critical diseases, such as systemic vasculitis,
malignancies and acute exacerbation of pulmonary fibrosis.
One patientmanifestingMPA at the firstmedical examination
was excluded from this study. Also, 17 patients with malig-
nancies, onepatientwith sepsis due to severepneumonia and
five patients whowere complicated by acute exacerbation of
the disease at initial presentation were also excluded.
Pulmonary function testing and bronchoalveolar
lavage procedure
Pulmonary function testing was performed on all 61 pa-
tients at initial presentation. The carbon monoxide diffus-
ing capacity was available in 51 patients.
Bronchoalveolar lavage (BAL) was performed on the
characterization of the inflammatory cellular population.
Briefly, a fiberoptic bronchoscope was wedged into the
middle lobe or lingula. Saline solution was instilled in 3
aliquots of 50 ml and then BAL fluid specimens from the
subjects were collected. After the total cell concentration
was calculated, the cells were cytospun at 400 rpm for
5 min and 300 cells were differentially counted.
Chest high-resolution computed tomography
scanning and histologic examination
All patients with IPF underwent chest high-resolution com-
puted tomography (HRCT) scanning at the time of initial pre-
sentation. The chest HRCTscanswere obtainedwith awindow
setting for lung parenchyma (window width, 1600e1800 HU;
window level, 600 to 700 HU) and mediastinum (window
width, 300e350 HU; window level, 25e40 HU).
A surgical lung biopsy was available in 26 patients. In the
MPO-ANCA positive IPF cases, a surgical biopsy was available
in 6 and postmortem examination in 2 patients. In three of
these patients, the biopsy was performed before MPO-ANCA
became positive. The kidney biopsies were available in six
patients with MPO-ANCA positivity. Five had needle biopsies
and one an autopsy specimen. SerumMPO-ANCAwas positive
at the time of kidney biopsy.
Measurement of MPO-ANCA
We measured MPO-ANCA in 61 IPF patients at the initial
hospital presentation and during the follow-up period.
Blood samples were obtained from clotted blood following
610 M. Ando et al.centrifugation at 1500  g at 4 C for 10 min, and stored at
80 C until the measurements were performed. MPO-
ANCA was measured using an enzyme-linked immunosorb-
ent assay kit (NIPRO, Japan) and the values above 20 EU
were considered to be positive.
Statistics
Statistical analyses were performed using SPSS II software
(SPSS Inc, Chicago, IL). Data are expressed as median and
range. The ManneWhitney U-test was applied to elucidate
the difference between the two independent groups.
Fisher’s exact probability test was used to compare
dichotomous variables between the two groups.
KaplaneMeier analysis was used to compare survival be-




The characteristics and laboratory findings of the study
population at initial hospital presentation are shown in
Table 1. We enrolled 61 patients including 46 men and 15
women. The median age was 68 years (range 40e82 years).
Forty-five patients were smokers.
The prevalence of MPO-ANCA and MPA in patients
with IPF
In three of 61 patients (4.9%), MPO-ANCA was positive at
the time of diagnosis (Table 1). All 61 patients were
followed-up in our hospital and chronologic measurement
of MPO-ANCA was performed until December 2010. During
the follow-up period (median 40 months; range, 1e121
months), six patients exhibited positive conversion of MPO-Table 1 Characteristics of study population at initial
hospital presentation.
Characteristics
Number of patients 61










ANA positive 31 (50.8%)
MPO-ANCA positive 3 (4.9%)
Abbreviations: IPF: idiopathic pulmonary fibrosis; WBC: white
blood counts; CRP: C reactive protein; LDH: lactate dehydro-
genase; Cre: creatinine; ANA: anti-nuclear antibody; ANCA:
anti-neutrophil cytoplasmic antibody; MPO: myeloperoxidase.ANCA. In contrast, negative conversion was not observed in
the MPO-ANCA-positive patients during the course of
observation without treatment. The total prevalence of
MPO-ANCA positivity in the 61 subjects was 14.8%.
Clinical characteristics of MPO-ANCA positive
pulmonary fibrosis
To clarify the characteristics of the MPO-ANCA-positive
pulmonary fibrosis, we evaluated the clinical, radiologic
and histologic characteristics of the nine patients positive
for MPO-ANCA (Table 2). Median age was 69 years (range,
57e75 years). All patients were men and smokers (2 current
smokers and 7 ex-smokers). Three patients were positive
for MPO-ANCA initially and 6 became positive during the
follow-up period. The median duration between initial IPF
diagnosis and conversion to MPO-ANCA positivity was 23
months (range. 0e71 months). The maximum levels of
MPO-ANCA titers ranged from 22 to 1460 EU. At the time of
detection, 3 patients presented with prolonged or recur-
rent fever, 2 patients presented with myalgia and a patient
demonstrated unintentional weight loss. Lung histopathol-
ogy was examined in 7 MPO-ANCA positive cases. A surgical
lung biopsy was performed for 6 patients and 3 of these
were examined prior to conversion. The histologic pattern
was consistent with that of usual interstitial pneumonia.
Alveolar hemorrhage or small vessel vasculitis was not
observed. Prominent lymphoid follicle proliferation was
observed in two cases. Postmortem examination of the lung
for two cases showed alveolar hemorrhage, but no evidence
of small vessel vasculitis. We also performed histopatho-
logic examination of the kidney by a needle biopsy or at
postmortem examination. We confirmed a diagnosis of MPA
in 2 cases based on findings of crescentic glomeruloneph-
ritis compatible with MPO-ANCA-related nephropathy. The
histopathological findings of the remaining 4 cases were
mesangial proliferative glomerulonephritis, chronic tubu-
lointerstitial nephritis, minor glomerular abnormalities,
and normal findings, respectively. Thus, they were not
diagnosed as MPO-ANCA related nephropathy. Three out of
9 patients (33%) with positive MPO-ANCA met UCTD criteria,
whereas only 2 out of 52 (3.8%) patients with negative
MPO-ANCA met the UCTD criteria. The prevalence of UCTD
in MPO-ANCA-positive cases was statistically higher than
that in MPO-ANCA-negative cases. (p Z 0.02).
Treatment and outcome
We retrospectively analyzed whether the treatment of the
MPO-ANCA-positive patients was different to that given to
IPF patients. As shown in Table 2, eight of nine (89%) patients
with positive MPO-ANCA were treated with corticosteroids,
whereas 26 of 52 (50%) patients with IPF were treated with
corticosteroids. There was a statistically significant differ-
ence (p Z 0.036). Immunosuppressants including azathio-
prine, cyclophosphamide or mizorbine were administered
for four (44%) patients with MPO-ANCA-positive fibrosis and
only one (2%) patients with IPF. Pirfenidone was given to
seven patients with IPF. Thus treatment was different be-
tween MPO-ANCA-positive fibrosis and IPF. As for MPO-ANCA-
positive fibrosis, the treatment was started for progressive
Table 2 Clinical and pathologic features of MPO-ANCA-positive pulmonary fibrosis.















Vasculitis Diagnosis Treatment Outcome
1 70 M Ex 120 ANA (1:80),
Jo-1(þ)





2 57 M Ex 171 ANA (1:80)
SS-A(þ)




3 69 M Cur 133 ANA (1:40) 69 Yes None UIP pattern N.D. IPF PSL Died
(acute
exacerbation)








UIP pattern N.D. UCTD PSL Died
(acute
exacerbation)
6 71 M Ex 22 RF 669 IU/ml 0 N.D. Fever UIP pattern N.D. UCTD PSL Survived
7 67 M Cur 31 ANA (1:40)
RF 90 IU/ml





8 58 M Ex 1400 N.D. 71 Yes None UIP pattern N.D. IPF PSL Survived
9 67 M Ex 24 ANA (1:40) 44 Yes None N.D. N.D. IPF None Survived
Abbreviations: Ex: Ex-smoker; Cur: current smoker; N.D.: not detected; UIP: usual interstitial pneumonia; MPA: microscopic polyangitis; UCTD: undifferentiated connective tissue disease;
IPF: idiopathic pulmonary fibrosis; PSL: prednisolone; AZP: azathioprine; CPA: cyclophosphamide; MZR: mizorbine; None: non-treatment.



















612 M. Ando et al.respiratory failure in four patients, for systemic vasculitis
with definite MPA diagnosis in two, for persistent fever in
one, and refractive myalgia in one. Six patients died during
the follow-up period. Four patients died of acute exacer-
bation of pulmonary fibrosis, one died of intractable pneu-
mothorax, and one died of cytomegalovirus infection. As for
IPF, therapy was started for progressive respiratory failure in
all patients. Eight patients died of acute exacerbation of
pulmonary fibrosis, 6 of progressive respiratory failure, 6 of
pneumonia and 3 of lung cancer. The median survival of pa-
tientswithMPO-ANCA-positive fibrosis and IPFwas 62months
(95% CI 29.13e94.87) and 63 months (95% CI 44.55e81.42),
respectively. There was no significant difference between
the two groups (pZ 0.9266).
High-resolution computed tomography
In the initial HRCT scans of the nine MPO-ANCA-positive
patients, there were subpleural reticular opacities, trac-
tion bronchiectasis and honeycombing (Fig. 1). These find-
ings were also frequently observed in MPO-ANCA-negative
cases. No differences were found between the two groups.
Characteristics of cases developing MPO-ANCA
positive conversion
In an attempt to predict which cases would develop
MPO-ANCA positivity, we compared data between
MPO-ANCA-positive and -negative PF patients (Table 3). At
the time of first medical examination, the positive anti-
nuclear antibodies were found in 65% of the patients with
MPO-ANCA-positive fibrosis and 50% of IPF. The incidence of
positive anti-nuclear antibodies was not different between
the two groups (p Z 0.488). Among several autoantibodies,
the positive rate of rheumatoid factor or RA test of
MPO-ANCA-positive fibrosis was significantly higher than thatFigure 1 High-resolution computed tomography scans of nine M
monary fibrosis (IPF). A; case 1; B, case 2; C, case 3; D, case 4, E,of IPF (p Z 0.006). As for pulmonary function test, value of
carbon monoxide diffusion capacity (DLCO) of the MPO-
ANCA-positive cases was lower than that of the negative
group. The percentage of BALF eosinophils in the MPO-ANCA-
positive group was higher than that in the negative group
(p Z 0.04). Low attenuation areas on HRCT were observed
more frequently in the MPO-ANCA-positive group as com-
pared with the MPO-ANCA-negative group (p Z 0.02).
Discussion
This report is the first to describe the prevalence and
chronology of MPO-ANCA positivity and MPA in consecutive
patients with an initial diagnosis of IPF. In the present
study, 3 of 61 patients exhibited positive MPO-ANCA titers
when first evaluated. During follow-up six addition patients
became positive for MPO-ANCA. Thus, the prevalence of
MPO-ANCA positivity increased over time. Among the nine
patients with positive MPO-ANCA titers, the development of
systemic vasculitis was confirmed in two.
In the present study, we measured MPO-ANCA for con-
secutive patients with an initial diagnosis of IPF and the
prevalence of MPO-ANCA at the initial presentation was 4.9%
and increased to 14.8% during the follow-up period. Previ-
ously, Nozu and colleagues reported higher prevalence of
MPO-ANCA positivity. They showed that 19 patients (35.8%)
were ANCA-positive (17 patientswith positiveMPO-ANCA and
2 patients with positive proteinase 3-ANCA). However there
may be a selection bias in their study because ANCA was
measured based only on the referring doctor’s decision
resulting in relatively high percentage of female patients.13
Previously reported series indicated that IPF precedes
the development of vasculitis in the majority cases.9,14e17
The precise mechanism of MPO-ANCA production in IPF,
however, remains unclear. Given that MPO-ANCA is often
detected in patients with suppurative respiratory diseasePO-ANCA-positive cases initially diagnosed with idiopathic pul-
case 5; F, case 6; G, case 7; H, case 8; I, case 9.
Table 3 Comparisons between patients with pulmonary fibrosis developing MPO-ANCA-positive conversion and patients with
MPO-ANCA-negative idiopathic pulmonary fibrosis.
Characteristics MPO-ANCA negative MPO-ANCA positive p value
Number of patients 52 9
Age, yr 69 (50e82) 69 (57e75) 0.541
Male/female 37/15 9/0 0.064
Smoking status
Never-smoker 16 (31.0%) 0 (0%) 0.051
Smoker 36 (69.0%) 9 (100%)
Cough 33 (63.5%) 3 (33.3%) 0.093
DOE 29 (56.9%) 7 (77.8%) 0.193
Fever 4 (7.7%) 1 (11.1%) 0.563
Laboratory findings
WBC 6715 (3400e11,900) 8850 (5420e15,100) 0.055
CRP 0.19 (0.01e4.92) 2.16 (0.06e9.83) 0.084
LDH 270 (90e710) 227 (148e457) 0.903
Cre 0.77 (0.19e1.64) 0.88 (0.61e1.52) 0.590
ANA, positive 26/52 (50%) 6/9 (67%) 0.488
RA test or RF, positive 5/46 (11%) 4/6 (66%) 0.006
Anti-SSA, positive 1/48 (2%) 1/6 (17%) 0.212
Anti-SS-B, positive 1/48 (2%) 0/5 (0%) 1.000
Anti-dsDNA, positive 1/43 (2%) 1/7 (14%) 0.263
Anti-Sm, positive 1/47 (2%) 1/6 (17%) 0.216
Anti-Scl70, positive 6/47 (13%) 0/5 (0%) 1.000
Anti-RNP, positive 2/46 (4%) 0/6 (0%) 1.000
Anti-Jo1, positive 4/47 (9%) 1/6 (17%) 1.000
Anti-centromere, positive 2/19 (11%) 0/3 (0%)
Pulmonary function test
%VC 75.7 (39.8e119.1) 66.9 (54.1e89.2) 0.888
FEV1.0% 82.8 (69.3e112) 82.5 (75.6e89.4) 0.672
%DLco 63.9 (22.7e96.4) (n Z 44) 41.6 (22.1e79.6) (n Z 7) 0.040
BAL, fluid, %
Number of patients 46 6
Total cells concentration 2.33 (0.9e7.44) 2.5 (1.00e3.55) 0.927
Macrophage 88 (34.7e99.0) 72.8 (41.4e87.5) 0.020
Lymphocytes 6.3 (0.6e31.3) 7.25 (2.0e13.0) 0.669
Neutrophils 3.0 (0e57.0) 6.7 (1.5e54.0) 0.222
Eosinophils 1.3 (0e10.3) 5.4 (0.9e14.5) 0.003
HRCT findings
Groud-glass opacities 52 (100%) 9 (100%) e
Interlobular septal thickning 52 (100%) 9 (100%) e
Traction bronchiectasis 46 (88.4%) 9 (100%) 0.283
Consolidation 11 (26.8%) 1 (11.1%) 0.484
Honeycombing 42 (80.8%) 9 (100%) 0.175
Low attenuation areas 18 (34.6%) 8 (88.8%) 0.002
Abbreviations: DOE: dyspnea on effort; WBC: white blood cell count; CRP: C-reactive protein; Cre: creatinine; ANA: anti-nuclear
antibody; RF: rheumatoid factor; VC: vital capacity; FEV1%: predicted forced expiratory volume in 1 s; %DLco; predicted percent value of
diffuse capacity of carbon monoxide; BAL; bronchoalveolar lavage.
Bold value signifies ManneWhitney U-test, Fisher’s extract probability test, p < 0.05, statistically significant.
MPO-ANCA in the course of IPF 613and diffuse panbronchiolitis,18,19 it may be possible that
MPO-ANCA would be produced as a result of neutrophil
destruction during the chronic inflammation process.
HRCTsubpleural reticular opacities, tractionbronchiectasis
and honeycombing were observed in all MPO-ANCA-positive
subjects, however these findings were also found in
MPO-ANCA-negative IPF patients (80.8%). Nozu and colleagues
reported a similar result: honeycombing was observed in 73%
patients with ANCA-positive pulmonary fibrosis and in 54.8%
patients with ANCA-negative pulmonary fibrosis.13Corresponding to the CT findings, the lung histopathology of
MPO-ANCApositive pulmonaryfibrosismatched thepattern for
usual interstitial pneumonia in an autopsy series of 11 cases, in
which vasculitis was observed in 5 cases.20 Our series add
new data of the biopsy histopathology by examining 6
MPO-ANCA-positive patients before the development of MPA.
Moreover, three patients were examined before MPO-ANCA
positive conversion. As a result, the histopathologic pattern
was compatible with the usual interstitial pneumonia pattern
and no alveolar hemorrhage or small vessel vasculitis was
614 M. Ando et al.observed in the lung specimens in any of the cases. Thus, it is
difficult to clearly discriminate the MPO-ANCA-positive and
MPO-ANCA-negative cases among patients with IPF based on
radiologic and histologic findings, but honeycombing which is
themost characteristic finding of IPFwithMPO-ANCApositivity
would be a stretch of one’s imagination. In contrast, after MPA
occurs, various CT findings including ground-glass attenuation,
consolidation and nodules are observed in ANCA-positive lung
fibrosis.21
In this series, we reviewed nine IPF patients with MPO-
ANCA at initial presentation or during follow-up. Interest-
ingly, they were all smokers and frequently demonstrated
low attenuation areas on their HRCT scans and also showed
lower DLco in comparison with MPO-ANCA-negative cases.
Similarly, Foulon et al. reported that cumulative cigarette
smoking tended to be higher in ANCA-positive patients with
pulmonary fibrosis than in ANCA-negative controls.22 A
previous report by Sessa et al. described a higher preva-
lence of smoking in patients with rapidly progressive glo-
merulonephritis due to ANCA associated small vessel
vasculitis.23 Cigarette smoke is likely associated with MPO
expression on epithelial cells and induces neutrophilic
infiltration into the lung tissue through proinflammatory
cytokine production.24 Abundant MPO in the lung tissue
might contribute to the generation of MPO-ANCA.
In patients who acquired MPO-ANCA we sought to
determine the factors which predict this conversion. These
patients had BAL eosinophilia and a higher coincidence of
low attenuation areas on HRCT. We recommend measure-
ment of MPO-ANCA during follow-up periods if these fea-
tures were present initially.
MPA is a serious complication in MPO-ANCA-positive pa-
tients. Foulon and colleagues reported that MPA occurred in
5 of 6 (83.3%) patients with MPO-ANCA positivity and pul-
monary fibrosis.22 In our study, MPA was histologically
diagnosed in 2 of 9 (22.2%) patients with positive MPO-
ANCA, which may indicate a lower prevalence of MPA.
The difference in the prevalence may be due to a recall
bias with identification of the ANCA-positive patients with
vasculitis in the previous study.11
Rheumatologic studies have estimated that as many as
25% of patients with features of a systemic autoimmune
disease do not fulfill American College of Rheumatology
(ACR) classification criteria for connective tissue disease
(CTD). These patients are considered to have diffuse or
undifferentiated connective tissue disease (UCTD).25e29
Kinder et al. recently showed that the majority of pa-
tients (83%) who met the UCTD criteria had distinct radio-
logical and pathological features of NSIP, whereas the
frequency of the patient with IPF/UIP who met the UCTD
was unusual (6%).11 Also, Corte et al. demonstrated that
UCTD was present in 31% of NSIP and 13% of IPF.30 In our
study, five of 61 patients (8.2%) diagnosed as IPF at first
presentation met the UCTD criteria, suggesting that the
UCTD seems to be uncommon manifestation in the patients
with IPF. In this study, three out of nine patients (33%) with
MPO-ANCA-positive pulmonary fibrosis met the UCTD cri-
teria and two (22%) did the criteria for diagnosis of MPA.
MPO-ANCA-positive pulmonary fibrosis may be a phenotype
with CTD background among IPF. Our series contained three
patients who had prolonged fever and/or myalgia with high
MPO-ANCA titers. They did not satisfy the MPA criteria,however the patients were immediately treated with im-
munosuppressants. This finding suggests that early inter-
vention could prevent the progression of vasculitis.
Homma and colleagues showed that positive MPO-ANCA is
an unfavorable prognostic factor in patients with pulmonary
fibrosis.20 In addition, Nozu and colleagues demonstrated
that a high titer of ANCA is associatedwith a poor prognosis as
well as the occurrence of MPA.13 In the present study, 5 of 6
patients with MPO-ANCA titers over 100 EU died, while 2 of 3
patientswith titers below 100 EU survived, which agreedwith
thedatabyNozuet al.13On thewhile, thecumulative survival
rate of MPO-ANCA-positive cases after diagnosis of IPF was
comparable to that of MPO-ANCA-negative IPF patients.
However, vasculitis appeared to be well controlled in most
cases. Our data indicate that serial measurement of
MPO-ANCA and early intervention may improve the outcome
of MPO-ANCA positive pulmonary fibrosis.
This study demonstrated occasional MPO-ANCA positive
conversion in IPF patients and among those that show
conversion, some develop MPA. BAL eosinophilia and low
attenuation areas on HRCT scans may predict the positive
conversion of MPO-ANCA. Because the sample size of this
study is small, we cannot determine the precise incidence
of MPO-ANCA positivity in IPF. However, this follow-up
survey is of significant value to show that MPO-ANCA con-
version can occur in the IPF patients in a certain ratio. In
the future, further prospective study should be required.
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